Methadone and prolongation of QT interval
- there is a risk of QT interval prolongation in patients taking methadone, especially those on high doses (1)
- there is evidence that very-high-dose methadone may be associated with torsade de pointes (2)
- recommended that patients with the following risk factors for QT interval prolongation are carefully monitored whilst taking methadone:
- heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 inhibitors, or medicines with the potential to cause QT interval prolongation (1)
- also any patient requiring more than 100mg of methadone per day should be closely monitored (1)
- the RCGP guidance also notes that the risk of QT-interval prolongation may be dose-dependent (3)
- "..methadone may be a risk factor for QT prolongation and torsade de pointes with a possible dose-dependent action... recommends monitoring for patients on high dose methadone (>100 mg daily) and with other QT interval prolongation risk factors where appropriate.."
- heart or liver disease, electrolyte abnormalities, concomitant treatment with CYP 3A4 inhibitors, or medicines with the potential to cause QT interval prolongation (1)
Reference:
- (1) Current Problems in Pharmacovigilance 2006;31:1-12.
- (2) Krantz MJ et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002 Sep 17;137(6):501-4.
- (3) RCGP (2007). Drug misuse and dependence: UK guidelines on clinical management
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page